FDA amended EUA for COVID bivalent mRNA technology booster (April 18th) (Pfzier-BioNTech & Moderna for original & BA4/BA5 clades); then CDC's ACIP advisory group met April 19th, 2023

by Paul Alexander

April 23, 2023

VRBPAC (Jan 26th 2023); for this 'simplified' approach Dr. Wiseman below outlines the FAILURE & risk of the FDA & CDC decisions given no supporting data, omission of VAERS data on stroke signals

Dr. David Weisman (excellent scholarship) is lead scientist here:

ACIP April 19 2023: Bivalent primary series dosing with no directly supportive data and in the face of ever more resistant variants. Ischemic stroke signal in VAERS ignored. Written remarks CDC-2023-0028

SOURCE:

https://www.researchgate.net/publication/370132212_ACIP_April_19_2023_Bivalent_primary_series_dosing_with_no_directly_supportive_data_and_in_the_face_of_ever_more_resistant_variants_Ischemic_stroke_signal_in_VAERS_ignored_Written_remarks_CDC-2023-0028

Back to COVID-19 OP-EDs